Study on the Safety of the Drug Runcaciguat and How Well it Works When Given at the Highest Dose as Tolerated by Individual Patient Whose Kidneys Are Not Working Properly and Suffering at the Same Time From High Blood Sugar and/or High Blood Pressure and a Disease of the Heart and the Blood Vessels.
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 243 participants.
Also called NCT04507061
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 243 participants
- Sponsor
- Registry
-
NCT04507061 -
2019-003297-53
-
- Other papers using this trial's data
- The soluble guanylate cyclase activator runcaciguat significantly improves albuminuria in patients with chronic kidney disease: a randomized placebo-controlled clinical trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Austria, Belgium, Bulgaria, Denmark, Finland, Germany, Israel, Italy, Poland, Slovakia, Spain, Sweden, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT04507061. Randomized; quadruple masking; primary purpose treatment. Start 2020-09-01 (actual); primary completion 2022-03-08 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study on the Safety of the Drug Runcaciguat and How Well it Works When Given at the Highest Dose as Tolerated by Individual Patient Whose Kidneys Are Not Working Properly and Suffering at the Same Time From High Blood Sugar and/or High Blood Pressure and a Disease of the Heart and the Blood Vessels.
- Acronym
- CONCORD
- Condition
- Chronic Kidney Disease
- Intervention (Drug)
- runcaciguat
- Intervention (Other)
- Placebo
- Lead sponsor
- Bayer
Record details
- Record id
cardio:ct-nct04507061- Content hash
be272ecd8e8d41b54cb0412955bd24672118a109423e8710e8c184e471cb757a